Back to search results
NCT03032601

Physiological Effects of N-Acetyl Cysteine in Patients With Multiple Sclerosis

Enrolling by Invitation
NAAges 18+InterventionalSupportive care
Thomas Jefferson University
~55 participants
Updated 2025-09-17 on ClinicalTrials.gov
What's tested:N-acetyl Cysteine

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Changes in the metabolic activity in the brain, and improved parameters with regard to the inflammation associated with the active lesions based on both MRI and PET findings.
Measured over Baseline and 60 ± 30 days

Conditions

Multiple Sclerosis

Explore related trials

Multiple Sclerosis

Where it's being run

1 sites across 1 states
Pennsylvania1

Study leadership

  • Daniel A Monti, MD, MBA · PRINCIPAL_INVESTIGATOR · Thomas Jefferson University

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Clinical diagnosis of relapsing remitting MS or progressive MS who do not plan to start a medication during the study, or on stable disease modifying medication (interferon, glatiramer, dimethyl fumarate, teriflunomide).
Age 18 years old to no upper limit
Physically independent, ambulatory
Women of childbearing potential will confirm a negative pregnancy test and must practice effective contraception during the period of pilot study. In addition, male subjects who have a partner of childbearing age should practice effective contraception.
Participants must be able to complete study procedures in the greater Philadelphia area.

Exclusion

Patients are excluded who have received treatment with intravenous steroids within the past 90 days for reasons other than MS
Previous brain surgery that would interfere with determination of cerebral metabolism or structure on the FDG PET-MRI.
Score on Mini-Mental Status examination of 20 or lower.
Wheelchair-bound or bed-ridden, non-ambulatory.
Intracranial abnormalities that may complicate interpretation of the brain scans (e.g., stroke, tumor, vascular abnormality affecting the target area).
History of head trauma with loss of consciousness \> 48 hours.
History of asthma requiring daily medications for adequate management.
Any medical disorder or physical condition that could reasonably be expected to interfere with the assessment of MS symptoms, or with any of the study assessments including the PET-MRI imaging.
Patients with evidence of a significant psychiatric disorder by history/examination that would prevent completion of the study will not be allowed to participate.
Patients with current alcohol or drug abuse
Pregnant or lactating women.
Enrollment in active clinical trial/ experimental therapy within the prior 30 days.
Pending surgery during the course of the study.
Patients taking medications that might interact with NAC involved in this study will be evaluated on a case by case basis by the PI or study physician. These medications include: Medications for high blood pressure; Medications that slow blood clotting; Medications for diabetes; Nitroglycerin.
Patients with history of pulmonary hypertension.
Any neurological, psychiatric, or medical condition that might affect the distribution of the radiopharmaceutical in the body or brain (as determined by Investigator)
Currently using medications that might alter the distribution of radiopharmaceuticals in - -the body or brain (as determined by Investigator)
Patient exceeds the weight limit of the table
Claustrophobia that would prevent completion of imaging studies
Glucose level that would interfere with the FDG PET scan
Any additional contraindications for MRI; Has metallic objects (e.g., pacemakers) in the body

What this trial measures

  • Changes in the metabolic activity in the brain, and improved parameters with regard to the inflammation associated with the active lesions based on both MRI and PET findings.Baseline and 60 ± 30 days

    The goal would be to find a shorter duration of active lesions, reduced impact of the lesions on metabolic activity in the brain, and improved parameters with regard to the inflammation associated with the active lesions based on both MRI and PET findings. Changes on the PET and MRI scans would be correlated with changes in clinical findings and quality of life measures.